Cargando…

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types

Recent advances in human immunology have led to the identification of novel immune cell subsets and the biological function of many of these subsets has now been identified. The recent US Food and Drug Administration approval of several immunotherapeutics for the treatment of a variety of cancer typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepone, Lauren M., Donahue, Renee N., Grenga, Italia, Metenou, Simon, Richards, Jacob, Heery, Christopher R., Madan, Ravi A., Gulley, James L., Schlom, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548330/
https://www.ncbi.nlm.nih.gov/pubmed/28936253
http://dx.doi.org/10.5772/62322
_version_ 1783255821579190272
author Lepone, Lauren M.
Donahue, Renee N.
Grenga, Italia
Metenou, Simon
Richards, Jacob
Heery, Christopher R.
Madan, Ravi A.
Gulley, James L.
Schlom, Jeffrey
author_facet Lepone, Lauren M.
Donahue, Renee N.
Grenga, Italia
Metenou, Simon
Richards, Jacob
Heery, Christopher R.
Madan, Ravi A.
Gulley, James L.
Schlom, Jeffrey
author_sort Lepone, Lauren M.
collection PubMed
description Recent advances in human immunology have led to the identification of novel immune cell subsets and the biological function of many of these subsets has now been identified. The recent US Food and Drug Administration approval of several immunotherapeutics for the treatment of a variety of cancer types and the results of ongoing immunotherapy clinical studies requires a more thorough interrogation of the immune system. We report here the use of flow cytometry-based analyses to identify 123 immune cell subsets of peripheral blood mononuclear cells. The use of these panels defines multiple differences in younger (< 40 years) vs. older (≥ 40 years) individuals and between aged-matched apparently healthy individuals and metastatic cancer patients, aspects not seen in the analysis of the following standard immune cell types: CD8, CD4, natural killer, natural killer-T, regulatory T, myeloid derived suppressor cells, conventional dendritic cells (DCs), plasmacytoid DCs and B cells. The use of these panels identifying 123 immune cell subsets may aid in the identification of patients who may benefit from immunotherapy, either prior to therapy or early in the immunotherapeutic regimen, for the treatment of cancer or other chronic or infectious diseases.
format Online
Article
Text
id pubmed-5548330
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55483302017-09-21 Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types Lepone, Lauren M. Donahue, Renee N. Grenga, Italia Metenou, Simon Richards, Jacob Heery, Christopher R. Madan, Ravi A. Gulley, James L. Schlom, Jeffrey J Circ Biomark Original Research Article Recent advances in human immunology have led to the identification of novel immune cell subsets and the biological function of many of these subsets has now been identified. The recent US Food and Drug Administration approval of several immunotherapeutics for the treatment of a variety of cancer types and the results of ongoing immunotherapy clinical studies requires a more thorough interrogation of the immune system. We report here the use of flow cytometry-based analyses to identify 123 immune cell subsets of peripheral blood mononuclear cells. The use of these panels defines multiple differences in younger (< 40 years) vs. older (≥ 40 years) individuals and between aged-matched apparently healthy individuals and metastatic cancer patients, aspects not seen in the analysis of the following standard immune cell types: CD8, CD4, natural killer, natural killer-T, regulatory T, myeloid derived suppressor cells, conventional dendritic cells (DCs), plasmacytoid DCs and B cells. The use of these panels identifying 123 immune cell subsets may aid in the identification of patients who may benefit from immunotherapy, either prior to therapy or early in the immunotherapeutic regimen, for the treatment of cancer or other chronic or infectious diseases. SAGE Publications 2016-03-10 /pmc/articles/PMC5548330/ /pubmed/28936253 http://dx.doi.org/10.5772/62322 Text en © 2016 Author(s). Licensee InTech. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Article
Lepone, Lauren M.
Donahue, Renee N.
Grenga, Italia
Metenou, Simon
Richards, Jacob
Heery, Christopher R.
Madan, Ravi A.
Gulley, James L.
Schlom, Jeffrey
Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
title Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
title_full Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
title_fullStr Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
title_full_unstemmed Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
title_short Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
title_sort analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detected in analysis of standard immune cell types
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548330/
https://www.ncbi.nlm.nih.gov/pubmed/28936253
http://dx.doi.org/10.5772/62322
work_keys_str_mv AT leponelaurenm analysesof123peripheralhumanimmunecellsubsetsdefiningdifferenceswithageandbetweenhealthydonorsandcancerpatientsnotdetectedinanalysisofstandardimmunecelltypes
AT donahuereneen analysesof123peripheralhumanimmunecellsubsetsdefiningdifferenceswithageandbetweenhealthydonorsandcancerpatientsnotdetectedinanalysisofstandardimmunecelltypes
AT grengaitalia analysesof123peripheralhumanimmunecellsubsetsdefiningdifferenceswithageandbetweenhealthydonorsandcancerpatientsnotdetectedinanalysisofstandardimmunecelltypes
AT metenousimon analysesof123peripheralhumanimmunecellsubsetsdefiningdifferenceswithageandbetweenhealthydonorsandcancerpatientsnotdetectedinanalysisofstandardimmunecelltypes
AT richardsjacob analysesof123peripheralhumanimmunecellsubsetsdefiningdifferenceswithageandbetweenhealthydonorsandcancerpatientsnotdetectedinanalysisofstandardimmunecelltypes
AT heerychristopherr analysesof123peripheralhumanimmunecellsubsetsdefiningdifferenceswithageandbetweenhealthydonorsandcancerpatientsnotdetectedinanalysisofstandardimmunecelltypes
AT madanravia analysesof123peripheralhumanimmunecellsubsetsdefiningdifferenceswithageandbetweenhealthydonorsandcancerpatientsnotdetectedinanalysisofstandardimmunecelltypes
AT gulleyjamesl analysesof123peripheralhumanimmunecellsubsetsdefiningdifferenceswithageandbetweenhealthydonorsandcancerpatientsnotdetectedinanalysisofstandardimmunecelltypes
AT schlomjeffrey analysesof123peripheralhumanimmunecellsubsetsdefiningdifferenceswithageandbetweenhealthydonorsandcancerpatientsnotdetectedinanalysisofstandardimmunecelltypes